ITCA placebo

OTHER2 trials

Sponsors

Intarcia Therapeutics

Conditions

Type 2 Diabetes

Phase 3

A Study to Evaluate Cardiovascular Outcomes in Patients With Type 2 Diabetes Treated With ITCA 650

CompletedNCT01455896

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-03-31End: 2016-03-31Updated: 2017-01-27

A Study to Evaluate ITCA 650 for the Treatment of Type 2 Diabetes

CompletedNCT01455857

Intarcia TherapeuticsType 2 Diabetes

Start: 2013-03-31End: 2014-09-30Updated: 2015-08-18

Related Papers

Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial.

2021-12-0664 citations

Implications of cardiovascular outcome trials with injectable antidiabetic agents

Journal of Diabetes2018-07-044 citations